Seminars in Oncology
Volume 30, Issue 5 , Pages 678-688 , October 2003

Endothelin receptor antagonists in the treatment of prostate cancer

  • Lance K Lassiter

      Affiliations

    • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    • ,
  • Michael A Carducci

      Affiliations

    • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    • Corresponding Author InformationAddress reprint requests to Michael A. Carducci, MD, Division of Medical Oncology, Room 1M-89, Cancer Research Building, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Baltimore, MD 21231, USA

References 

  1. Jemal A, Murray T, Samuels A, et al.  Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26
  2. Huggins C, Hodges CV. Studies on prostate cancer (The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate). Cancer Res. 1941;1:293–297
  3. Kantoff PW, Halabi S, Conaway M, et al.  Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer (Results of the Cancer and Leukemia Group B 9182 study). J Clin Oncol. 1999;17:2506–2513
  4. Newling DW, Denis L, Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer (Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer—Genitourinary Group Study 30853). Cancer. 1993;72:3793–3798
  5. Savarese DM, Halabi S, Hars V, et al.  Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer (a final report of CALGB 9780.Cancer and Leukemia Group B). J Clin Oncol. 2001;19:2509–2516
  6. Inoue A, Yanagisawa M, Kimura S, et al.  The human endothelin family (Three structurally and pharmacologically distinct isopeptides predicted by three separate genes). Proc Natl Acad Sci USA. 1989;86:2863–2867
  7. Kopetz ES, Nelson JB, Carducci MA. Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest New Drugs. 2002;20:173–182
  8. Levin ER. Endothelins. N Engl J Med. 1995;333:356–363
  9. Nelson JB, Bagnato A, Battistini B, et al.  The endothelin axis (Emerging role in cancer). Nat Rev Cancer. 2003;3:110–116
  10. Wu-Wong JR. Endothelin receptor antagonists as therapeutic agents for cancer. Curr Opin Invest Drugs. 2002;3:1234–1239
  11. Yanagisawa M, Kurihara H, Kimura S, et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415
  12. Arai H, Hori S, Aramori I, et al.  Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348:730–732
  13. Sakurai T, Yanagisawa M, Takuwa Y, et al.  Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990;348:732–735
  14. Xu D, Emoto N, Giaid A, et al.  ECE-1 (A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1). Cell. 1994;78:473–485
  15. Goldie RG. Endothelins in health and disease (An overview). Clin Exp Pharmacol Physiol. 1999;26:145–148
  16. Battistini B, Chailler P, D’Orleans-Juste P, et al.  Growth regulatory properties of endothelins. Peptides. 1993;14:385–399
  17. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate. 2000;44:77–87
  18. Clozel M. Endothelin receptor antagonists (Current status and perspectives). J Cardiovasc Pharmacol. 2000;35(suppl):S65–S68
  19. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists (Therapeutic considerations for a novel class of cardiovascular drugs). Circulation. 2000;102:2434–2440
  20. Opgenorth TJ. Endothelin receptor antagonism. Adv Pharmacol. 1995;33:1–65
  21. Remuzzi G, Perico N, Benigni A. New therapeutics that antagonize endothelin (Promises and frustrations). Nat Rev Drug Discov. 2002;1:986–1001
  22. Bloch KD, Friedrich SP, Lee ME, et al.  Structural organization and chromosomal assignment of the gene encoding endothelin. J Biol Chem. 1989;264:10851–10857
  23. Daub H, Weiss FU, Wallasch C, et al.  Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature. 1996;379:557–560
  24. Nelson JB, Hedican SP, George DJ, et al.  Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1:944–949
  25. Nelson JB, Chan-Tack K, Hedican SP, et al.  Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 1996;56:663–668
  26. Valdenaire O, Rohrbacher E, Mattei MG. Organization of the gene encoding the human endothelin-converting enzyme (ECE-1). J Biol Chem. 1995;270:29794–29798
  27. Dahlof B, Gustafsson D, Hedner T, et al.  Regional haemodynamic effects of endothelin-1 in rat and man (unexpected adverse reaction). J Hypertens. 1990;8:811–817
  28. Davar G, Hans G, Fareed MU, et al.  Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport. 1998;9:2279–2283
  29. De Melo JD, Tonussi CR, D’Orleans-Juste P, et al.  Articular nociception induced by endothelin-1, carrageenan and LPS in naive and previously inflamed knee-joints in the rat (Inhibition by endothelin receptor antagonists). Pain. 1998;77:261–269
  30. Dymshitz J, Vasko MR. Endothelin-1 enhances capsaicin-induced peptide release and cGMP accumulation in cultures of rat sensory neurons. Neurosci Lett. 1994;167:128–132
  31. Piovezan AP, D’Orleans-Juste P, Souza GE, et al.  Endothelin-1-induced ET(A) receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw (Modulation by simultaneous ET(B) receptor activation). Br J Pharmacol. 2000;129:961–968
  32. Raffa RB, Schupsky JJ, Jacoby HI. Endothelin-induced nociception in mice (Mediation by ETA and ETB receptors). J Pharmacol Exp Ther. 1996;276:647–651
  33. Yoshizawa T, Kimura S, Kanazawa I, et al.  Endothelin localizes in the dorsal horn and acts on the spinal neurones (Possible involvement of dihydropyridine-sensitive calcium channels and substance P release). Neurosci Lett. 1989;102:179–184
  34. Nelson JB, Lee WH, Nguyen SH, et al.  Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res. 1997;57:35–37
  35. Battistini B, D’Orleans-Juste P, Sirois P. Endothelins (Circulating plasma levels and presence in other biologic fluids). Lab Invest. 1993;68:600–628
  36. Bremnes T, Paasche JD, Mehlum A, et al.  Regulation and intracellular trafficking pathways of the endothelin receptors. J Biol Chem. 2000;275:17596–17604
  37. Burkhardt M, Barton M, Shaw SG. Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1 (Differential effects of acute and chronic ETA receptor blockade). J Hypertens. 2000;18:273–279
  38. Vijayaraghavan J, Scicli AG, Carretero OA, et al.  The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem. 1990;265:14150–14155
  39. Chiao JW, Moonga BS, Yang YM, et al.  Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer. 2000;83:360–365
  40. Masaki T, Miwa S, Sawamura T, et al.  Subcellular mechanisms of endothelin action in vascular system. Eur J Pharmacol. 1999;375:133–138
  41. Vacca F, Bagnato A, Catt KJ, et al.  Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res. 2000;60:5310–5317
  42. Wu-Wong JR, Opgenorth TJ. Endothelin and isoproterenol counter-regulate cAMP and mitogen-activated protein kinases. J Cardiovasc Pharmacol. 1998;31(suppl 1):S185–S191
  43. Shichiri M, Kato H, Marumo F, et al.  Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells. Hypertension. 1997;30:1198–1203
  44. Wu-Wong JR, Chiou WJ, Dickinson R, et al.  Endothelin attenuates apoptosis in human smooth muscle cells. Biochem J. 1997;328:733–737
  45. Wu-Wong JR, Chiou WJ, Wang J. Extracellular signal-regulated kinases are involved in the antiapoptotic effect of endothelin-1. J Pharmacol Exp Ther. 2000;293:514–521
  46. Del Bufalo D, Di Castro V, Biroccio A, et al.  Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis (Requirement for Akt activation). Mol Pharmacol. 2002;61:524–532
  47. Eberl LP, Egidy G, Pinet F, et al.  Endothelin receptor blockade potentiates FasL-induced apoptosis in colon carcinoma cells via the protein kinase C-pathway. J Cardiovasc Pharmacol. 2000;36:S354–S356
  48. Eberl LP, Valdenaire O, Saintgiorgio V, et al.  Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells. Int J Cancer. 2000;86:182–187
  49. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27–31
  50. Weidner N, Carroll PR, Flax J, et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401–409
  51. Bagnato A, Salani D, Di Castro V, et al.  Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma (Evidence for an autocrine role in tumor growth). Cancer Res. 1999;59:720–727
  52. Salani D, Taraboletti G, Rosano L, et al.  Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol. 2000;157:1703–1711
  53. Spinella F, Rosano L, Di Castro V, et al.  Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem. 2002;277:27850–27855
  54. Strohmeyer D, Rossing C, Bauerfeind A, et al.  Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate. 2000;45:216–224
  55. Rosano L, Varmi M, Salani D, et al.  Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res. 2001;61:8340–8346
  56. Rosano L, Salani D, Di Castro V, et al.  Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin Sci (Lond). 2002;103(suppl 48):306S–309S
  57. Boyce BF, Yoneda T, Guise TA. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer. 1999;6:333–347
  58. Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer. 2000;88:2892–2898
  59. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer. 2003;97:779–784
  60. Mundy GR. Metastasis to bone (Causes, consequences and therapeutic opportunities). Nat Rev Cancer. 2002;2:584–593
  61. Nelson JB, Nguyen SH, Wu-Wong JR, et al.  New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology. 1999;53:1063–1069
  62. Alam AS, Gallagher A, Shankar V, et al.  Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility (Implications for the vascular control of bone resorption). Endocrinology. 1992;130:3617–3624
  63. Samara E, Dutta S, Cao G, et al.  Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist. J Clin Pharmacol. 2001;41:397–403
  64. Carducci MA, Nelson JB, Bowling MK, et al.  Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas (Safety and pharmacokinetics). J Clin Oncol. 2002;20:2171–2180
  65. Ryan CW, Janus T, Vogelzang NJ, et al.  A phase I study of men and women with refractory malignancies given daily dosing of an endothelin receptor antagonist. Proc Am Soc Clin Oncol. 2000;19:783; (abstr)
  66. Carducci MA, Padley RJ, Breul J, et al.  Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer (A randomized, phase II, placebo-controlled trial). J Clin Oncol. 2003;21:679–689
  67. Carducci MA, Vogelzang NJ, Daliani DD, et al.  A placebo controlled phase II dose-ranging evaluation of an endothelin-A receptor antagonist for men with hormone refractory prostate cancer (HRPCA) and disease related pain. Proc Am Assoc Cancer Res. 2000;41:1314; (abstr)
  68. Nelson JB, Nabulsi AA, Vogelzang NJ, et al.  Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol. 2003;169:1143–1149
  69. Singh A, Padley RJ, Talat A. The selective endothelin receptor-A antagonist atrasentan improves quality of life adjusted time to progression (QATTP) in hormone refractory prostate cancer patients. Proc Am Soc Clin Oncol. 2001;20:1567; (abstr)
  70. Carducci MA, Nelson JB, Humerickhouse RA, et al.  Effects of atrasentan on progression and survival in men with hormone refractory prostate cancer (Follow-up to study M96–594). Proc Am Soc Clin Oncol. 2002;21:708; (abstr 708)
  71. Abbott Laboratories Provides Update on Phase III Atrasentan Clinical Trials in Men with Advanced Prostate Cancer. 2003; http://abbott.com/news/press_release.cfm?id=533. Feb 10
  72. Yang J, Fizazi K, Peleg S, et al.  Endothelin-1 dependent and independent mechanisms concur in the increased bone mass of prostate cancer bone metastases. Proc Am Assoc Can Res. 2002;43:1562; (abstr)

☆ Supported by Abbott Laboratories. M.A.C. is a paid consultant for Abbott Laboratories. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.

PII: S0093-7754(03)00353-1

doi: 10.1016/S0093-7754(03)00353-1

Seminars in Oncology
Volume 30, Issue 5 , Pages 678-688 , October 2003

Article Tools